0
Special Section on Optical Diagnostic Imaging from Bench to Bedside Combined Imaging

Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study

[+] Author Affiliations
Natasha Shah, Jessica Gibbs, Dulcy Wolverton, Albert Cerussi, Nola Hylton, Bruce J. Tromberg

University of California–Irvine, Beckman Laser Institute and Medical Clinic, Laser Microbeam and Medical Program, Irvine, California 92162-1475 and University of California–San Francisco, Magnetic Resonance Science Center, San Francisco, California

J. Biomed. Opt. 10(5), 051503 (December 07, 2004February 28, 2005March 10, 2005October 31, 2005). doi:10.1117/1.2070147
History: Received December 07, 2004; Revised February 28, 2005; Accepted March 10, 2005; Published October 31, 2005
Text Size: A A A

Monitoring tumor response to therapy can enable assessment of treatment efficacy, maximizing patient outcome and survival. We employ a noninvasive, handheld laser breast scanner (LBS) based on broadband diffuse optical spectroscopy (DOS) in conjunction with contrast-enhanced magnetic resonance imaging (cMRI) to assess tumor response to presurgical neoadjuvant chemotherapy. DOS and cMRI scans are performed after the first and fourth cycles of a doxorubicin/cyclophosphamide regimen in a patient with invasive ductal carcinoma. DOS measurements are used to quantify bulk tissue optical and physiological parameters, which are mapped to T2- and T1-weighted cMRI images. Initial DOS measurements show high tumor/normal contrast in total hemoglobin concentration (THC, 56±7 versus 27±4μM) and water fraction (81.4±1% versus 24±3%) colocalized with regions of strongly enhancing T2-wieghted and cMRI signals. After the fourth cycle of chemotherapy, we observe decreases in peak MRI contrast-enhancement values (37.6%) and apparent lesion volume (21.9 versus 13.7cm3), which corresponds to physiological changes measured by DOS, including a 20 to 25% reduction in the spatial extent of the tumor and a 38.7% drop in mean total hemoglobin content (THC, 41.6 versus 23.4μM). These data provide in vivo validation of the accuracy of broadband DOS and the sensitivity of optical methods to changes in tumor physiology.

Figures in this Article
© 2005 Society of Photo-Optical Instrumentation Engineers

Citation

Natasha Shah ; Jessica Gibbs ; Dulcy Wolverton ; Albert Cerussi ; Nola Hylton, et al.
"Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study", J. Biomed. Opt. 10(5), 051503 (December 07, 2004February 28, 2005March 10, 2005October 31, 2005). ; http://dx.doi.org/10.1117/1.2070147


Access This Article
Sign In to Access Full Content
Please Wait... Processing your request... Please Wait.
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
 
Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

PubMed Articles
Advertisement

Buy this article ($18 for members, $25 for non-members).
Sign In